Treatment of tristetraproline (TTP) related diseases by inhibition of natural antisense transcript to TTP
First Claim
Patent Images
1. A synthetic, modified oligonucleotide of 10 to 30 nucleotides in length comprising at least one modification wherein the at least one modification is selected from:
- at least one modified sugar moiety;
at least one modified internucleotide linkage;
at least one modified nucleotide, and combinations thereof;
wherein said oligonucleotide is an antisense compound which is at least 90% complementary to its target and is (i) is a single-stranded oligonucleotide of 10 to 30 nucleotides in length or (ii) is a siRNA of 19-30 nucleotides in length wherein both (i) and (ii) specifically hybridizes to a target comprising a complementary region of a natural antisense polynucleotide of a Tristetraproline (TTP) polynucleotide selected from the group consisting of SEQ ID NOS;
3, 4 or 5 and upregulates the function and/or expression of a Tristetraproline (TTP) gene in vivo or in vitro as compared to a normal control wherein, when the oligonucleotide is a siRNA, said siRNA targets a non-overlapping, complementary region of said natural antisense polynucleotide.
1 Assignment
0 Petitions
Accused Products
Abstract
The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of Tristetraproline (TTP), in particular, by targeting natural antisense polynucleotides of Tristetraproline (TTP). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of TTP.
-
Citations
16 Claims
-
1. A synthetic, modified oligonucleotide of 10 to 30 nucleotides in length comprising at least one modification wherein the at least one modification is selected from:
- at least one modified sugar moiety;
at least one modified internucleotide linkage;
at least one modified nucleotide, and combinations thereof;
wherein said oligonucleotide is an antisense compound which is at least 90% complementary to its target and is (i) is a single-stranded oligonucleotide of 10 to 30 nucleotides in length or (ii) is a siRNA of 19-30 nucleotides in length wherein both (i) and (ii) specifically hybridizes to a target comprising a complementary region of a natural antisense polynucleotide of a Tristetraproline (TTP) polynucleotide selected from the group consisting of SEQ ID NOS;
3, 4 or 5 and upregulates the function and/or expression of a Tristetraproline (TTP) gene in vivo or in vitro as compared to a normal control wherein, when the oligonucleotide is a siRNA, said siRNA targets a non-overlapping, complementary region of said natural antisense polynucleotide. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15)
- at least one modified sugar moiety;
-
16. A method of preventing or treating a disease associated with at least one Tristetraproline (TTP) polynucleotide and/or at least one encoded product thereof, comprising:
- administering to a patient a therapeutically effective dose of at least one antisense oligonucleotide of 10 to 30 nucleotides in length that binds and specifically hybridizes to a natural antisense sequence of said at least one Tristetraproline (TTP) polynucleotide selected from the group consisting of SEQ ID NOS;
3, 4 and 5 and upregulates expression of said at least one Tristetraproline (TTP) polynucleotide;
thereby treating the disease associated with the at least one Tristetraproline (TTP) polynucleotide and/or at least one encoded product thereof wherein the disease is selected from tristetraprolin-deficiency syndrome.
- administering to a patient a therapeutically effective dose of at least one antisense oligonucleotide of 10 to 30 nucleotides in length that binds and specifically hybridizes to a natural antisense sequence of said at least one Tristetraproline (TTP) polynucleotide selected from the group consisting of SEQ ID NOS;
Specification